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Vancomycin (VAN) has been associated with acute kidney injury (AKI) since it has been put into clinical use in the 1950’s. Early
reports of AKI were likely linked to the impurities of the VAN preparation. With the advent of the more puriﬁed forms of VAN, the
incidence of AKI related to VAN were limited to acute interstitial nephritis (AIN) or as a potentiating agent to other nephrotoxins
such as Aminoglycosides. VAN as the sole etiologic factor for nephrotoxic acute tubular necrosis (ATN) has not been described.
Here, we report a case of biopsy-proven ATN resulting from VAN.
1.Case
R. H. is a 23-year-old male with a history of childhood
acute lymphocytic leukemia in remission, neuroectodermal
tumor status postresection, and gamma knife therapy,
who presented to our Emergency Department (ED) with
complaints of fever and chills. He also noticed yellowish
drainage around the site of a peripherally inserted central
catheter (PICC). In the ED, patient was febrile to 101.7◦
Fahrenheitwithabloodpressureof113/83mmHgandpulse
of 134bpm. The PICC line was removed, and antibiotic
therapy initiated with piperacillin-tazobactam and VAN. RH
received 1gm IV of VAN in the ED, and upon admission to
the ﬂoor, received another 2gm IV. Piperacillin-tazobactam
was discontinued. Eight hours later, another 2 grams of
VAN were given, with cumulative dose of 5gm in 24hrs
(50mg/kg in 24 hours). Patient’s admission creatinine was
0.97mg/dL. The patient was 103kg and 72   tall. Attempting
to use a loading dose of 15mg/kg based on total body
weight [1], the patient was initiated on 2000mg of VAN per
hospital protocol of using VAN doses in 1000mg aliquots.
Standard pharmacokinetic equations with simpliﬁed one-
compartment models employing log-linear drug removal
were used for estimations [2]. With a volume of distribution
estimated at approximately 0.6L/kg of actual body weight
and a VAN clearance estimated to be at least 120mL/min
[3], the patient was expected to achieve an initial VAN
trough of approximately 8mg/L with steady state troughs
above 10mg/L with a dosing scheme of 2000mg given every
12 hours. As pharmacokinetic estimates in patients above
their average body weight exhibit substantial variability, the
patient was initiated on the aforementioned dose with a
measuredVANtroughplannedantecedenttothefourthdose
(to capture steady-state concentrations). Goal troughs and
monitoring schemes were performed according to national
VAN guidelines [4].
The following day, the serum creatinine was 3.62mg/dL.
He became oligo-anuric with a urine output of 50cc in
24 hours. Urinalysis revealed a bland urine sediment and
a urine sodium of 75meq/L and a fractional excretion of
sodium of 2.77%. He had not been exposed to IV contrast,
receivedanaminoglycosideorexposed toanyotherpotential
nephrotoxins.
Blood cultures were negative, and the PICC line tip cul-
tures were positive for Serratia marcescens. As the patient
experienced acute nephrotoxicity, VAN was ceased after
the third dose and ciproﬂoxacin initiated. The creatinine









Figure 1: Representative photographs of the renal biopsy showing tubular damage secondary to drug toxicity. In both panels (a) and (b) a
number of tubules show moderate degree of acute tubular necrosis (asterisks). Some of tubules contain hyaline or epithelial casts in their
lumina (green arrows), while several tubules show vacuolization of their cytoplasm (green arrowheads). One of the glomerular aﬀerent
arteriole shows swollen endothelia and occlusive change (black arrow).
Table 1: Laboratory and clinical parameters.
Day Scrmg/dl UO 24hrs VAN dose VAN S. Conc. HD
0 .97 NR 5gm ND No
1 3.62–4.26 50cc ND No
26 . 2 5<50cc ND No
38 . 4 1<50cc ND No
49 . 9 6<50cc 64.7 Yes
5 9.36 1000cc Yes
9 9.21 2000cc ND Yes
10 5.88 2500cc ND No
30 1.24 NR ND No
Scr—serum creatinine; UO—urine output; VAN—Vancomycin; S. Conc—
Serum concentration; HD—hemodialysis; ND—not done; NR—not re-
corded.
obstruction. On day 3, a renal biopsy was performed. The
main ﬁnding was ATN (Figure 1). Many tubules showed
moderate degree of vacuolization of their cytoplasm (green
arrows).Someoftubulescontainedhyalineorepithelialcasts
in their lumina (black arrows). The VAN serum concentra-
tion done on day 4 was 64.7mg/L, and hemodialysis was
initiated for volume overload. By day 5, his urine output
increased to 1L/day. On day 10, he was taken oﬀ hemodial-
ysis. His creatinine improved to 1.2mg/dL over the next few
weeks.
2. Discussion
VAN, a parenteral glycopeptide antibiotic, has been used
clinically since 1956. The original preparation contained
a number of impurities and was brown in color, hence,
the nickname “Mississippi Mud”. It is these impurities that
were thought to be responsible for certain toxicities such
as anaphylaxis, toxic epidermal necrolysis, erythema multi-
forme, ototoxicity, and nephrotoxicity [5, 6]. Between 1956
and 1986, 57 cases of VAN-associated nephrotoxicity were
described. More than 50% of the cases were identiﬁed within
the ﬁrst six years of VAN use when the product was relatively
impure [7]. As manufacturing processes improved and VAN
was puriﬁed, nephrotoxicity became less common [8], and
contemporary preparations seemed to nearly eliminate the
original adverse events.
In 1983, Farber andMoellering reported the incidence of
n e p h r o t o x i c i t yw i t hV A Nt ob e5 %[ 5]. This, however, was
a retrospective study, and it failed to evaluate whether the
A K Iw a sd u et oA I No rA T N .V A Ni na s s o c i a t i o nw i t ha n
aminoglycoside is known to be associated with an increased
incidence of nephrotoxicity presumed to be ATN [9, 10].
Other risk factors associated with nephrotoxicity include
prolonged therapy for >21 days, [9] higher APACHE scores,
[11] loop diuretics, and steady-state VAN concentration >
or = 28mg/L [12]. Recent studies have shown that doses
g r e a t e rt h a no re q u a lt o4g r a m sp e rd a y[ 13]a n dt r o u g h
concentrations greater than 15mg/L are associated with
nephrotoxicity [11, 14]. More speciﬁcally, when trough
concentrations are analyzed as a linear variable with classiﬁ-
cation and regression tree modeling, a threshold of 9.9mg/L
has been identiﬁed [15]. These studies, while instructive for
the association of VAN and toxicity, are limited by a failure
to control for weight-adjusted dose, and the retrospective
nature of the studies do not determine causality [11, 13–
15]. Instead, elevated VAN concentrations could be merely
anintermediatevariableinthepathwaytotheultimatecausal
event of renal failure by other mechanisms.
As VAN safety proﬁle improved and with the emerg-
ing prevalence of methicillin-resistant Staphylococcus aureus
(MRSA), VAN became one of the most frequently pre-
scribed intravenous anti-infective for treatment of these
infections [16]. With increasing the minimum inhibitory
concentrations for VAN and proper testing methodologies
for completing minimum inhibitory concentrations under
continual debate [17–20], the dire outcomes associated withInternational Journal of Nephrology 3
MRSA infections have lead many to seek novel treatment
strategies including increasing VAN doses and exposure.
Speciﬁcally, various national guidelines for serious infec-
tions have recommended that VAN troughs be maintained
between 15–20mg/L to ensure an AUC/MIC of ∼400 [21–
23]. Such a position has been substantiated on the basis of
appropriate pharmacodynamic targets, limited clinical data,
and the supposition that such a strategy is safe [21, 22,
24]. However, no study to date has prospectively evaluated
the impact of VAN exposure on renal endpoints and that
elevated doses (such as a 5 gram dose given in 24 hours in
our patient) could predispose patients to kidney injury.
The potential mechanism of action of VAN-associated
nephropathy has been studied in both humans and animals.
The energy-dependent transport mechanisms found in the
proximal tubular epithelium render the kidneys highly
susceptible to toxicant-induced renal injury. VAN exposure
in renal proximal tubule epithelial cells results in increased
cell proliferation as evidenced by increased number of cells,
totalprotein,andDNAsynthesis.VANenhancescellularATP
concentration and stimulates oxygen consumption, support-
ing its role as a stimulant of oxidative phosphorylation
[25]. The beneﬁcial eﬀect of some antioxidants like DL-α
lipoic acid, Melatonin, Ginkgo biloba and milrinone have
been shown to reduce the renal damage, suggesting the
involvement of free radicals in renal damage [26].
While it is unclear if VAN-associated acute tubular
necrosis is preventable, these data argue for prompt serum
VANmonitoringgiventherapidfunctionaldeclineofpatient
nephrologic function even before the patient was scheduled
to receive the 4th dose of therapeutically dosed VAN.
Additionally, these data may support previously published
literature suggesting that VAN doses >4g per day , and
patient body weights in excess of 101.4kg may predispose to
nephrotoxicity, [27] in this case, acute tubular necrosis.
3. Conclusion
The most common VAN-associated nephrotoxicity is AIN
[28–30]. Although an association with ATN has been de-
scribed, to our knowledge, VAN as the sole etiologic cause of
ATN has never been reported in adult patients [31, 32]. Our
ﬁndingssupporttheseretrospectiveassociations andprovide
evidence for contemporary VAN-associated ATN. Further
studies are needed to determine the safety proﬁle of targeting
higher VAN trough levels for serious infectious in light of the
potential for AKI.
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